CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade AbCellera Biologics Inc. - ABCL CFD

    4.81
    2.34%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 4.7
    Open* 4.51
    1-Year Change* -64.74%
    Day's Range* 4.51 - 4.82
    52 wk Range 3.87-14.15
    Average Volume (10 days) 1.37M
    Average Volume (3 months) 33.06M
    Market Cap 1.26B
    P/E Ratio -100.00K
    Shares Outstanding 290.17M
    Revenue 50.39M
    EPS -0.45
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date Feb 19, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 4.81 0.21 4.57% 4.60 4.83 4.49
    Nov 30, 2023 4.70 -0.06 -1.26% 4.76 4.84 4.54
    Nov 29, 2023 4.74 0.03 0.64% 4.71 5.00 4.67
    Nov 28, 2023 4.70 0.22 4.91% 4.48 4.76 4.36
    Nov 27, 2023 4.50 0.17 3.93% 4.33 4.52 4.25
    Nov 24, 2023 4.40 0.05 1.15% 4.35 4.45 4.35
    Nov 22, 2023 4.40 0.02 0.46% 4.38 4.43 4.31
    Nov 21, 2023 4.31 -0.16 -3.58% 4.47 4.52 4.29
    Nov 20, 2023 4.57 0.18 4.10% 4.39 4.66 4.31
    Nov 17, 2023 4.43 0.11 2.55% 4.32 4.45 4.27
    Nov 16, 2023 4.36 -0.10 -2.24% 4.46 4.46 4.22
    Nov 15, 2023 4.50 0.16 3.69% 4.34 4.63 4.26
    Nov 14, 2023 4.30 0.15 3.61% 4.15 4.34 4.10
    Nov 13, 2023 3.96 -0.02 -0.50% 3.98 4.00 3.91
    Nov 10, 2023 4.01 -0.02 -0.50% 4.03 4.03 3.87
    Nov 9, 2023 4.02 -0.08 -1.95% 4.10 4.24 4.02
    Nov 8, 2023 4.16 -0.15 -3.48% 4.31 4.35 4.09
    Nov 7, 2023 4.36 -0.04 -0.91% 4.40 4.50 4.25
    Nov 6, 2023 4.44 -0.16 -3.48% 4.60 4.76 4.41
    Nov 3, 2023 4.67 0.71 17.93% 3.96 4.73 3.96

    AbCellera Biologics Inc. Events

    Time (UTC) Country Event
    Monday, February 19, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Abcellera Biologics Inc Earnings Release
    Q4 2023 Abcellera Biologics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 485.424 375.203 233.155 11.6115 8.83056
    Revenue 485.424 375.203 233.155 11.6115 8.83056
    Total Operating Expense 268.913 170.79 80.824 15.7285 9.58317
    Selling/General/Admin. Expenses, Total 66.755 48.761 15.752 4.01153 2.86219
    Research & Development 107.879 62.062 29.393 10.1129 5.80252
    Depreciation / Amortization 27.843 14.451 4.836 1.60408 0.91846
    Operating Income 216.511 204.413 152.331 -4.11701 -0.75261
    Interest Income (Expense), Net Non-Operating 12.034 -2.75 -2.818 0.13181 -0.5325
    Other, Net 10.554 17.486 8.32 1.7745 1.59397
    Net Income Before Taxes 239.099 219.149 157.833 -2.2107 0.30885
    Net Income After Taxes 158.519 153.464 118.918 -2.2107 0.30885
    Net Income Before Extra. Items 158.519 153.464 118.918 -2.2107 0.30885
    Net Income 158.519 153.464 118.918 -2.2107 0.30885
    Total Adjustments to Net Income 0 -0.01695
    Income Available to Common Excl. Extra. Items 158.519 153.464 118.918 -2.2107 0.29191
    Income Available to Common Incl. Extra. Items 158.519 153.464 118.918 -2.2107 0.29191
    Diluted Net Income 158.519 153.464 118.918 -2.2107 0.29191
    Diluted Weighted Average Shares 314.827 318.294 269.498 265.565 265.565
    Diluted EPS Excluding Extraordinary Items 0.50351 0.48215 0.44126 -0.00832 0.0011
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS 0.50351 0.48215 0.4516 -0.00832 0.0011
    Unusual Expense (Income) 3.7
    Other Operating Expenses, Total 66.436 45.516 27.143
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 10.056 12.192 21.545 101.383 45.917
    Revenue 10.056 12.192 21.545 101.383 45.917
    Total Operating Expense 61.445 77.066 59.323 63.648 54.313
    Selling/General/Admin. Expenses, Total 19.362 18.905 15.706 16.881 17.532
    Research & Development 36.473 52.647 28.245 26.582 26.685
    Depreciation / Amortization 5.61 5.514 13.818 5.15 4.886
    Other Operating Expenses, Total 0 0 1.554 15.035 5.21
    Operating Income -51.389 -64.874 -37.778 37.735 -8.396
    Interest Income (Expense), Net Non-Operating 10.779 9.759 12.034
    Other, Net 2.606 6.967 -5.668 8.852 1.51
    Net Income Before Taxes -38.004 -48.148 -31.412 46.587 -6.886
    Net Income After Taxes -30.528 -40.11 -29.893 26.624 -6.785
    Net Income Before Extra. Items -30.528 -40.11 -29.893 26.624 -6.785
    Net Income -30.528 -40.11 -29.893 26.624 -6.785
    Income Available to Common Excl. Extra. Items -30.528 -40.11 -29.893 26.624 -6.785
    Income Available to Common Incl. Extra. Items -30.528 -40.11 -29.893 26.624 -6.785
    Diluted Net Income -30.528 -40.11 -29.893 26.624 -6.785
    Diluted Weighted Average Shares 288.906 287.767 286.308 315.818 284.687
    Diluted EPS Excluding Extraordinary Items -0.10567 -0.13938 -0.10441 0.0843 -0.02383
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.10567 -0.13938 -0.10441 0.0843 -0.02383
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 1025.49 929.8 813.325 12.6403 15.1622
    Cash and Short Term Investments 886.485 722.977 595.019 9.67689 11.0399
    Cash & Equivalents 386.535 476.142 594.116 7.55292 10.4443
    Short Term Investments 499.95 246.835 0.903 2.12397 0.59558
    Total Receivables, Net 103.41 174.858 212.336 2.25386 3.57203
    Accounts Receivable - Trade, Net 38.593 160.576 212.336 1.15256 0.80888
    Prepaid Expenses 9.064 5.293 0.70959 0.55034
    Total Assets 1540.91 1318.57 1005.54 23.4881 21.4922
    Property/Plant/Equipment, Total - Net 217.255 111.616 17.923 8.47994 6.32994
    Property/Plant/Equipment, Total - Gross 235.73 121.442 23.509 11.6369 7.88282
    Accumulated Depreciation, Total -18.475 -9.826 -5.586 -3.15696 -1.55288
    Note Receivable - Long Term 0 1.78302 0
    Other Long Term Assets, Total 46.331 30.642 8.388 0.58478 0
    Total Current Liabilities 118.32 120.676 103.49 7.89486 6.43338
    Payable/Accrued 14.828 14.924 7.13 1.64337 1.51822
    Accrued Expenses 12.037 3.652 0.675 0.41914 0
    Notes Payable/Short Term Debt 0 0 0 0.38725 0
    Current Port. of LT Debt/Capital Leases 0.19 2.07973 2.53135
    Other Current Liabilities, Total 91.455 102.1 95.495 3.36537 2.38381
    Total Liabilities 307.63 292.836 175.028 13.2359 9.88297
    Total Long Term Debt 0 0 2.198 1.36314 0.91122
    Long Term Debt 2.198 1.36314 0.91122
    Other Liabilities, Total 156.132 134.79 43.179 3.97792 2.53837
    Total Equity 1233.28 1025.73 830.508 10.2521 11.6092
    Preferred Stock - Non Redeemable, Net 0 7.54585 7.55701
    Common Stock 734.365 722.43 710.387 5.12175 5.07369
    Additional Paid-In Capital 74.118 35.357 5.919 2.30018 1.48344
    Retained Earnings (Accumulated Deficit) 426.185 267.666 114.202 -4.71563 -2.50494
    Total Liabilities & Shareholders’ Equity 1540.91 1318.57 1005.54 23.4881 21.4922
    Total Common Shares Outstanding 286.852 283.257 269.498 265.565 265.565
    Other Current Assets, Total 25 25 5.97
    Goodwill, Net 47.806 47.806 31.5
    Intangibles, Net 131.502 148.392 115.153
    Long Term Investments 72.522 50.313 19.247
    Deferred Income Tax 33.178 37.37 26.161
    Total Inventory 1.532 1.672
    Other Equity, Total -1.391 0.28
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 919.518 930.735 940.653 1025.49 1045.67
    Cash and Short Term Investments 785.84 795.694 796.495 886.485 868.206
    Cash & Equivalents 172.422 179.747 193.017 386.535 371.973
    Total Receivables, Net 75.483 86.233 99.569 103.41 105.964
    Accounts Receivable - Trade, Net 37.446 45.678 20.003 38.593 105.964
    Total Inventory 1.194 1.447 1.447 1.532
    Prepaid Expenses 32.001 22.361 18.142 9.064
    Total Assets 1512.19 1537.17 1497.92 1540.91 1552.41
    Property/Plant/Equipment, Total - Net 277.209 259.64 233.187 217.255 200.602
    Property/Plant/Equipment, Total - Gross 304.239 283.847 254.52 235.73 216.339
    Accumulated Depreciation, Total -27.03 -24.207 -21.333 -18.475 -15.737
    Goodwill, Net 47.806 47.806 47.806 47.806 47.806
    Intangibles, Net 124.076 126.747 128.845 131.502 142.548
    Long Term Investments 62.887 58.792 57.583 72.522 66.718
    Other Long Term Assets, Total 80.694 113.446 89.845 46.331 49.066
    Total Current Liabilities 110.239 118.905 89.591 118.32 106.052
    Payable/Accrued 17.432 21.025 17.569 14.828 9.319
    Accrued Expenses 11.923 9.812 7.66 12.037 28.084
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 80.884 88.068 64.362 91.455 68.649
    Total Liabilities 329.415 342.339 289.419 307.63 302.237
    Total Long Term Debt 0 0 0 0 0
    Long Term Debt
    Deferred Income Tax 33.178 33.178 33.426 33.178 34.143
    Other Liabilities, Total 185.998 190.256 166.402 156.132 162.042
    Total Equity 1182.78 1194.83 1208.5 1233.28 1250.17
    Common Stock 747.914 744.756 742.816 734.365 730.427
    Additional Paid-In Capital 109.384 96.423 81.63 74.118 64.384
    Retained Earnings (Accumulated Deficit) 326.937 355.547 386.075 426.185 456.078
    Total Liabilities & Shareholders’ Equity 1512.19 1537.17 1497.92 1540.91 1552.41
    Total Common Shares Outstanding 289.778 289.189 288.427 286.852 285.762
    Other Equity, Total -1.46 -1.899 -2.021 -1.391 -0.717
    Other Current Assets, Total 25 25 25 25 71.499
    Short Term Investments 613.418 615.947 603.478 499.95 496.233
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line 158.519 153.464 118.918 -2.2107 0.30885
    Cash From Operating Activities 277.36 244.584 22.69 2.69372 3.56564
    Cash From Operating Activities 8.953 4.403 2.317 1.60408 0.91846
    Non-Cash Items 63.287 37.001 13.539 1.32723 0.42774
    Changes in Working Capital 29.825 41.672 -116.701 1.9731 1.91059
    Cash From Investing Activities -352.625 -332.247 -119.78 -5.77991 -5.30707
    Capital Expenditures -72.66 -58.452 -14.673 -3.99689 -5.30707
    Other Investing Cash Flow Items, Total -279.965 -273.795 -105.107 -1.78302 0
    Cash From Financing Activities -1.628 -3.886 683.653 0.19483 12.1857
    Issuance (Retirement) of Stock, Net 2.755 4.615 598.502 0.01416 10.2056
    Issuance (Retirement) of Debt, Net -0.323 -0.951 85.151 0.18067 1.98015
    Net Change in Cash -86.492 -92.974 586.563 -2.89137 10.4443
    Amortization 18.89 10.062 2.519
    Deferred Taxes -2.114 -2.018 2.098
    Financing Cash Flow Items -4.06 -7.55
    Foreign Exchange Effects -9.599 -1.425
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -40.11 158.519 188.412 161.788 168.573
    Cash From Operating Activities -44.063 277.36 246.448 373.234 100.219
    Cash From Operating Activities 2.858 8.953 6.212 3.681 1.391
    Amortization 2.656 18.89 7.844 5.213 2.606
    Deferred Taxes -2.114
    Non-Cash Items 13.446 63.287 43.148 26.226 12.675
    Changes in Working Capital -22.913 29.825 0.832 176.326 -85.026
    Cash From Investing Activities -149.609 -352.625 -335.562 -53.568 -26.371
    Capital Expenditures -14.984 -72.66 -60.33 -45.817 -14.495
    Other Investing Cash Flow Items, Total -134.625 -279.965 -275.232 -7.751 -11.876
    Cash From Financing Activities -0.458 -1.628 -1.977 -1.958 -3.131
    Financing Cash Flow Items -0.948 -4.06 -4.06 -4.06 -5
    Issuance (Retirement) of Stock, Net 0.49 2.755 2.406 2.175 1.941
    Issuance (Retirement) of Debt, Net -0.323 -0.323 -0.073 -0.072
    Foreign Exchange Effects -0.213 -9.599 -9.963 -1.411 -0.204
    Net Change in Cash -194.343 -86.492 -101.054 316.297 70.513
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Thermopylae Holdings Ltd Corporation 19.3576 56012493 153000 2023-05-26 LOW
    Baillie Gifford & Co. Investment Advisor 9.1115 26364751 6535100 2023-06-30 LOW
    Baker Bros. Advisors LP Hedge Fund 5.6851 16450180 6000000 2023-06-30 LOW
    Thiel (Peter A. J.D.) Individual Investor 4.9629 14360427 0 2023-04-24 LOW
    Voya Investment Management LLC Investment Advisor/Hedge Fund 3.6717 10624185 -213840 2023-06-30 LOW
    Lecault (Veronique) Individual Investor 3.2936 9530340 20000 2023-09-12 LOW
    Capital World Investors Investment Advisor 2.9101 8420493 -907000 2023-06-30 LOW
    Credit Suisse Funds AG Investment Advisor/Hedge Fund 1.5809 4574523 -33574 2023-06-30 LOW
    Baillie Gifford Overseas Ltd. Investment Advisor 1.5726 4550522 0 2023-08-31 LOW
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 1.4449 4180768 0 2023-06-30 LOW
    Founders Fund Venture Capital 1.4448 4180547 0 2023-06-30 LOW
    ArrowMark Colorado Holdings, LLC Investment Advisor/Hedge Fund 1.4187 4105095 4105095 2023-06-30 MED
    Lazard Asset Management, L.L.C. Investment Advisor/Hedge Fund 1.1319 3275301 32102 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 1.1293 3267618 2060920 2023-06-30 HIGH
    Federated Hermes International Investment Advisor/Hedge Fund 1.1246 3254000 446935 2023-06-30 LOW
    Prosight Capital Hedge Fund 0.8813 2550000 1796472 2023-06-30 HIGH
    Renaissance Technologies LLC Hedge Fund 0.8766 2536603 -274900 2023-06-30 HIGH
    Casdin Capital, LLC Hedge Fund 0.8709 2520000 0 2023-06-30 LOW
    Citadel Advisors LLC Hedge Fund 0.7582 2193770 719890 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.6975 2018226 -9039634 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    AbCellera Biologics Inc. Company profile

    AbCellera Biologics Inc. (ABCL) is a Canadian biotechnology company that develops antibody discovery platforms. Its full-stack, AI-powered drug discovery platform searches and analyses the database of natural immune systems to find antibodies that can be used by its partners to develop into drugs. 

    ABCL was established in 2012 as a spin-off from the University of British Columbia (UBC), where Dr Carl Hansen, the company’s founding CEO, was a faculty member from 2005 to 2019.

    The Vancouver-based company has collaborations with drug developers ranging from large cap pharmaceuticals to small biotechnology firms. As of the earnings date of 31 December 2021, the company had 156 discovery programmes either completed, in progress or under contract with 36 partners.

    As a recent example, AbCellera Biologics teamed with pharma giant Eli Lilly (LLY) to co-develop two antibody therapeutics to treat and prevent Covid-19 utilising ABCL’s technological stack.

    Some of the pharmaceutical companies that partnered with ABCL in the past two years include Everest Medicines for oncology or cancer; Kodiak Sciences (KOD) for partnership in eye care, Novarties (NVS), and Gilead Sciences (GILD) for infectious disease. 

    AbCellera Biologics was listed as a public company and began trading on the NASDAQ stock exchnage under the ticker symbol ‘ABCL’ in December 2020 through an initial public offering (IPO). ABCL’s stock price was set at $20.

    You can follow the ups and downs of the ABCL’s stock price at Capital.com. Also, stay on top of the latest AbCellera Biologics’ stock price developments with our live ABCL stock chart.

    Industry: Biotechnology & Medical Research (NEC)

    2215 Yukon Street
    VANCOUVER
    BRITISH COLUMBIA V5Y 0A1
    CA

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    Oil - Crude

    73.79 Price
    -1.040% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    US100

    15,939.70 Price
    -0.350% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Gold

    2,086.52 Price
    +0.630% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    XRP/USD

    0.63 Price
    +1.360% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading